Literature DB >> 11402113

Presenilin-1-associated abnormalities in regional cerebral perfusion.

K A Johnson1, F Lopera, K Jones, A Becker, R Sperling, J Hilson, J Londono, I Siegert, M Arcos, S Moreno, L Madrigal, J Ossa, N Pineda, A Ardila, M Roselli, M S Albert, K S Kosik, A Rios.   

Abstract

OBJECTIVE: To investigate the influence of the presenilin-1 gene (PS-1) mutation on regional cerebral perfusion, SPECT was evaluated in 57 individuals. The subjects were members of a large pedigree from Colombia, South America, many of whom carry a PS-1 mutation for early-onset AD.
METHODS: Members of this large kindred who were cognitively normal and did not carry the PS-1 mutation (n = 23) were compared with subjects who were carriers of the mutation but were asymptomatic (n = 18) and with individuals with the mutation and a clinical diagnosis of AD (n = 16). Cerebral perfusion was measured in each subject using hexamethylpropyleneamine oxime SPECT. The data were analyzed in two ways: 1) Mean cerebral perfusion in each of 4320 voxels in the brain was compared among the groups using t-tests (t-maps); and 2) each individual received a weighted score on 20 vectors (factors), based on a large normative sample (n = 200), using a method known as singular value decomposition (SVD).
RESULTS: Based on t-maps, subjects with the PS-1 mutation who were asymptomatic demonstrated reduced perfusion in comparison with the normal control subjects in the hippocampal complex, anterior and posterior cingulate, posterior parietal lobe, and anterior frontal lobe. The AD patients demonstrated decreased perfusion in the posterior parietal and superior frontal cortex in comparison with the normal control subjects. Discriminant function analysis of the vector scores derived from SVD (adjusted for age and gender) accurately discriminated 86% of the subjects in the three groups (p < 0.0005).
CONCLUSION: Regional cerebral perfusion abnormalities based on SPECT are detectable before development of the clinical symptoms of AD in carriers of the PS-1 mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402113     DOI: 10.1212/wnl.56.11.1545

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease.

Authors:  R A Sperling; J F Bates; E F Chua; A J Cocchiarella; D M Rentz; B R Rosen; D L Schacter; M S Albert
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

2.  Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task.

Authors:  John M Ringman; Luis D Medina; Meredith Braskie; Yaneth Rodriguez-Agudelo; Daniel H Geschwind; Miguel A Macias-Islas; Jeffrey L Cummings; Susan Bookheimer
Journal:  Cereb Cortex       Date:  2010-08-20       Impact factor: 5.357

3.  Familial risk for Alzheimer's disease alters fMRI activation patterns.

Authors:  Susan Spear Bassett; David M Yousem; Catherine Cristinzio; Ivana Kusevic; Michael A Yassa; Brian S Caffo; Scott L Zeger
Journal:  Brain       Date:  2006-05       Impact factor: 13.501

4.  Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease.

Authors:  Meredith N Braskie; Luis D Medina; Yaneth Rodriguez-Agudelo; Daniel H Geschwind; Miguel Angel Macias-Islas; Paul M Thompson; Jeffrey L Cummings; Susan Y Bookheimer; John M Ringman
Journal:  Hum Brain Mapp       Date:  2012-07-17       Impact factor: 5.038

Review 5.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.

Authors:  Eric M Reiman; Jessica B S Langbaum; Pierre N Tariot
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 6.  Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease.

Authors:  Cátia Janota; Cynthia A Lemere; Maria Alexandra Brito
Journal:  Mol Neurobiol       Date:  2015-07-05       Impact factor: 5.590

7.  Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.

Authors:  Nathan A Johnson; Geon-Ho Jahng; Michael W Weiner; Bruce L Miller; Helena C Chui; William J Jagust; Maria L Gorno-Tempini; Norbert Schuff
Journal:  Radiology       Date:  2005-03       Impact factor: 11.105

8.  Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

Authors:  J T Fuller; A Cronin-Golomb; J R Gatchel; D J Norton; E Guzmán-Vélez; H I L Jacobs; B Hanseeuw; E Pardilla-Delgado; A Artola; A Baena; Y Bocanegra; K S Kosik; K Chen; P N Tariot; K Johnson; R A Sperling; E M Reiman; F Lopera; Y T Quiroz
Journal:  J Prev Alzheimers Dis       Date:  2019

Review 9.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

10.  ERP generator anomalies in presymptomatic carriers of the Alzheimer's disease E280A PS-1 mutation.

Authors:  María A Bobes; Yuriem Fernández García; Francisco Lopera; Yakeel T Quiroz; Lídice Galán; Mayrim Vega; Nelson Trujillo; Mitchell Valdes-Sosa; Pedro Valdes-Sosa
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.